norketamine has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 1 studies
| Studies (norketamine) | Trials (norketamine) | Recent Studies (post-2010) (norketamine) | Studies (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) | Trials (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) | Recent Studies (post-2010) (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) |
|---|---|---|---|---|---|
| 220 | 32 | 122 | 3,859 | 8 | 1,052 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, L; Fujita, A; Fujita, Y; Hashimoto, K; Pu, Y | 1 |
1 other study(ies) available for norketamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
MPTP-induced dopaminergic neurotoxicity in mouse brain is attenuated after subsequent intranasal administration of (R)-ketamine: a role of TrkB signaling.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Anesthetics, Dissociative; Animals; Brain; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Ketamine; Male; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Neostriatum; Neuroprotective Agents; Parkinson Disease; Protein-Tyrosine Kinases; Receptor, trkB; Signal Transduction; Substantia Nigra; Tyrosine 3-Monooxygenase | 2020 |